Below are the most recent publications written about "PTEN Phosphohydrolase" by people in Profiles.
-
Michel-Flutot P, Cheng L, Thomas SJ, Lisi B, Schwartz H, Lam S, Lyttle M, Jaffe DA, Smith G, Li S, Wright MC, Lepore AC. PTEN inhibition promotes robust growth of bulbospinal respiratory axons and partial recovery of diaphragm function in a chronic model of cervical contusion spinal cord injury. Exp Neurol. 2024 Aug; 378:114816.
-
Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G. PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination. Int J Mol Sci. 2022 Oct 25; 23(21).
-
Kao CY, Jiang J, Thompson W, Papoutsakis ET. miR-486-5p and miR-22-3p Enable Megakaryocytic Differentiation of Hematopoietic Stem and Progenitor Cells without Thrombopoietin. Int J Mol Sci. 2022 May 11; 23(10).
-
Kar AN, Lee SJ, Sahoo PK, Thames E, Yoo S, Houle JD, Twiss JL. MicroRNAs 21 and 199a-3p Regulate Axon Growth Potential through Modulation of Pten and mTor mRNAs. eNeuro. 2021 Jul-Aug; 8(4).
-
Lasota J, Kowalik A, Felisiak-Golabek A, Zieba S, Wang ZF, Miettinen M. New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs. Appl Immunohistochem Mol Morphol. 2019 01; 27(1):54-58.
-
Sementino E, Menges CW, Kadariya Y, Peri S, Xu J, Liu Z, Wilkes RG, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Testa JR. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol. 2018 11; 233(11):8952-8961.
-
Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieslik M, Chinnaiyan AM. Integrative clinical genomics of metastatic cancer. Nature. 2017 08 17; 548(7667):297-303.
-
Ronen S, Abbott DW, Kravtsov O, Abdelkader A, Xu Y, Banerjee A, Iczkowski KA. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform. Hum Pathol. 2017 07; 65:85-91.
-
Yao PL, Chen L, Dobrzanski TP, Zhu B, Kang BH, M?ller R, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-?/d inhibits human neuroblastoma cell tumorigenesis by inducing p53- and SOX2-mediated cell differentiation. Mol Carcinog. 2017 05; 56(5):1472-1483.
-
Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol. 2016 08; 29(8):904-14.